Over the next five years, Roche will invest USD 50 billion to expand and upgrade existing facilities and build new facilities across its Pharmaceutical and Diagnostics Division in the U.S.

The CRO is expanding its headquarters to include a comprehensive laboratory and rodent vivarium, which enhances its preclinical research infrastructure in the U.S.

The company’s MLD Advanced uses a combination of proven technologies to enable manufacturers to quickly and efficiently meet the requirements of high outputs.

As the bio/pharma industry faces the looming threat of tariffs, it is clearer than ever that reporting on the key issues and trends set to shape industry is imperative to help stakeholders stay informed.

In case you missed the recent virtual event hosted by Fierce Biotech, where J.D. Mowery, President, CDMO Division, Bora Pharmaceuticals, and Stephen Lam, Chief Executive Officer, Bora Biologics, tackled the issue of biologics’ supply, check out the key takeaways from the discussion here.

The monoclonal antibody therapy is now the first and only treatment approved for patients with IgG4-RD.

The Michael J. Fox Foundation for Parkinson’s Research and the Luxembourg National Research Fund have provided funding for two separate projects assessing Accure Therapeutics’ ACT-02 for the treatment of Parkinson’s disease.

A challenging biotech investment landscape is shaking up the industry and having a negative impact on multiple CDMOs in the space.

The radiopharmaceuticals CDMO will have a majority stake in Agilera Pharma, advancing its strategy of becoming a fully-integrated service provider in the radiopharmaceutical therapy sector.

Over the next five years, Novartis will be investing USD23 billion in 10 facilities, including seven new facilities.

Through analysis of historical vaccination program data, researchers have demonstrated a persistent link between the live-attenuated zoster vaccination and a lower incidence of dementia.